Wall Street Zen Downgrades Sana Biotechnology (NASDAQ:SANA) to Strong Sell

Sana Biotechnology (NASDAQ:SANA) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday.

Several other equities research analysts also recently issued reports on the company. Wedbush raised their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Morgan Stanley reaffirmed an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a report on Friday, March 13th. HC Wainwright cut their price target on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. Zacks Research downgraded Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 3rd. Finally, Bank of America raised their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $8.20.

Sana Biotechnology Trading Down 4.4%

NASDAQ SANA opened at $3.29 on Friday. The stock has a 50 day moving average of $3.44 and a 200-day moving average of $4.11. Sana Biotechnology has a 12 month low of $1.60 and a 12 month high of $6.55. The company has a market cap of $878.00 million, a PE ratio of -3.39 and a beta of 2.06.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, sell-side analysts predict that Sana Biotechnology will post -0.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC increased its position in shares of Sana Biotechnology by 4.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock worth $188,000 after purchasing an additional 2,023 shares during the period. Xponance LLC increased its position in shares of Sana Biotechnology by 25.6% in the fourth quarter. Xponance LLC now owns 13,068 shares of the company’s stock worth $53,000 after purchasing an additional 2,662 shares during the period. Creative Planning increased its position in shares of Sana Biotechnology by 5.3% in the third quarter. Creative Planning now owns 54,177 shares of the company’s stock worth $192,000 after purchasing an additional 2,719 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Sana Biotechnology by 29.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company’s stock worth $53,000 after purchasing an additional 2,943 shares during the period. Finally, Savant Capital LLC increased its position in shares of Sana Biotechnology by 5.6% in the third quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock worth $236,000 after purchasing an additional 3,500 shares during the period. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.